Cargando…
Observations following discontinuation of long-term denosumab therapy
SUMMARY: Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upo...
Autores principales: | McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., Lewiecki, E. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391373/ https://www.ncbi.nlm.nih.gov/pubmed/28144701 http://dx.doi.org/10.1007/s00198-017-3919-1 |
Ejemplares similares
-
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
por: McClung, M. R., et al.
Publicado: (2012) -
Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017) -
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
por: Adachi, Jonathan D., et al.
Publicado: (2017) -
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022) -
Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)